Mint Tower Capital Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Mint Tower Capital Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-3,000	Closed	–	–	477
2020 Q4	$0	Sell	3,000 -1,000	-25%	-$2.13K	﹤0.01%	396
2020 Q3	$9K	Buy	+4,000	New	+$11.4K	﹤0.01%	242
2020 Q2	–	Sell	-10,000	Closed	-$38K	–	349
2020 Q1	$38K	Sell	10,000 -7,500	-43%	-$24.7K	0.01%	212
2019 Q4	$53K	Buy	+17,500	New	+$45.5K	0.01%	211

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.82B AUM

WAM

Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Mint Tower Capital Management's BMY.RT Position: Q1 2021 in Review

Mint Tower Capital Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 3,000 shares.

Mint Tower Capital Management first reported a position in BMY.RT in Q4 2019 and held it in 4 quarters. The position peaked at $53K in Q4 2019. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

Mint Tower Capital Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
Mint Tower Capital Management sold 3,000 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021.
Mint Tower Capital Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 4 quarters.
Mint Tower Capital Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $53K in Q4 2019.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Mint Tower Capital Management's 13F filing for Q1 2021, filed 12 May 2021.